PMID- 34823323
OWN - NLM
STAT- MEDLINE
DCOM- 20220602
LR  - 20220716
IS  - 1308-5263 (Electronic)
IS  - 1300-7777 (Print)
IS  - 1300-7777 (Linking)
VI  - 39
IP  - 2
DP  - 2022 Jun 1
TI  - Assessment of Bone Marrow Biopsy and Cytogenetic Findings in Patients with 
      Multiple Myeloma.
PG  - 109-116
LID - 10.4274/tjh.galenos.2021.2021.0325 [doi]
AB  - OBJECTIVE: Multiple myeloma (MM) is a malignant condition characterized by the 
      accumulation of malignant plasma cells. Although MM remains incurable, the 
      survival of MM patients has improved considerably due to the application of 
      autologous stem cell transplantation, novel agents, and advanced treatment 
      strategies. This study aimed to determine the cytogenetic characterization and 
      bone marrow (BM) features of Turkish patients with MM. MATERIALS AND METHODS: 
      Eighty-five MM patients were admitted to Dokuz Eylul University Hospital in 
      Turkey. BM samples of these MM patients were subjected to cytogenetic analyses at 
      diagnosis and during therapy as a part of therapeutical and clinical evaluation. 
      A complete cytogenetic study was performed using the G-banding technique. 
      Fluorescence in situ hybridization (FISH) analysis was performed using 
      cytoplasmic immunoglobulin. The degree of BM fibrosis was determined using 
      reticulin histochemical staining. We determined the percentage of BM plasma cells 
      based on the extent of CD38 staining. RESULTS: Eighty-five MM patients were 
      retrospectively identified between 2015 and 2021. The median age was 63 (38-90) 
      years. Of the 85 patients, 60 (70.6%) were male and 25 (29.4%) were female. 
      Seventy-two (84.7%) cases had BM fibrosis at the time of diagnosis. The most 
      common was grade 2 fibrosis, recorded in 35 cases (41.2%). About 72.9% of the 
      patients showed more than 50% plasma cells. FISH analysis indicated the presence 
      of abnormal chromosomes in 37% (32/85) of the patients. The most frequent 
      abnormality was Immunoglobulin heavy-chain (IGH) translocation (21.3%). 
      CONCLUSION: Subgroup analysis of IGH mutations is crucial in the identification 
      of high-risk MM patients. We believe that our study will contribute to the 
      determination of BM biopsy and cytogenetic features of MM patients in our 
      country.
FAU - Seyhanli, Ahmet
AU  - Seyhanli A
AUID- ORCID: 0000-0001-6082-2995
AD  - Sivas Numune Hospital, Clinic of Hematology, Sivas, Turkey
FAU - Yavuz, Boran
AU  - Yavuz B
AUID- ORCID: 0000-0002-3799-0461
AD  - Dokuz Eylul University Faculty of Medicine, Department of Hematology, Izmir, 
      Turkey
FAU - Aksit, Zehra
AU  - Aksit Z
AUID- ORCID: 0000-0003-3638-4491
AD  - Dokuz Eylul University Faculty of Medicine, Department of Internal Medicine, 
      Izmir, Turkey
FAU - Yuce, Zeynep
AU  - Yuce Z
AD  - Dokuz Eylul University Faculty of Medicine, Department of Medical Biology, Izmir, 
      Turkey
FAU - Ozkal, Sermin
AU  - Ozkal S
AUID- ORCID: 0000-0002-8167-0238
AD  - Dokuz Eylul University Faculty of Medicine, Department of Pathology, Izmir, 
      Turkey
FAU - Altungoz, Oguz
AU  - Altungoz O
AUID- ORCID: 0000-0002-2548-4238
AD  - Dokuz Eylul University Faculty of Medicine, Department of Medical Biology, Izmir, 
      Turkey
FAU - Demirkan, Fatih
AU  - Demirkan F
AUID- ORCID: 0000-0002-1172-8668
AD  - Dokuz Eylul University Faculty of Medicine, Department of Hematology, Izmir, 
      Turkey
FAU - Alacacioglu, Inci
AU  - Alacacioglu I
AUID- ORCID: 0000-0002-8187-7159
AD  - Dokuz Eylul University Faculty of Medicine, Department of Hematology, Izmir, 
      Turkey
FAU - Ozsan, Guner Hayri
AU  - Ozsan GH
AUID- ORCID: 0000-0002-0930-6300
AD  - Dokuz Eylul University Faculty of Medicine, Department of Hematology, Izmir, 
      Turkey
LA  - eng
PT  - Journal Article
DEP - 20211126
PL  - Turkey
TA  - Turk J Haematol
JT  - Turkish journal of haematology : official journal of Turkish Society of 
      Haematology
JID - 9606065
RN  - 0 (Immunoglobulins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biopsy
MH  - Bone Marrow/pathology
MH  - Cytogenetic Analysis/methods
MH  - Female
MH  - Fibrosis
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Immunoglobulins
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Male
MH  - Middle Aged
MH  - *Multiple Myeloma/diagnosis/genetics/therapy
MH  - Retrospective Studies
MH  - Transplantation, Autologous
PMC - PMC9160703
OTO - NOTNLM
OT  - Bone marrow biopsy
OT  - Multiple myeloma
OT  - Cytogeneticanalysis
OT  - Fluorescence in situ hybridization
COIS- Conflict of Interest: No conflict of interest was declared by the authors.
EDAT- 2021/11/27 06:00
MHDA- 2022/06/03 06:00
PMCR- 2022/06/01
CRDT- 2021/11/26 01:15
PHST- 2021/11/26 01:15 [entrez]
PHST- 2021/11/27 06:00 [pubmed]
PHST- 2022/06/03 06:00 [medline]
PHST- 2022/06/01 00:00 [pmc-release]
AID - 52069 [pii]
AID - 10.4274/tjh.galenos.2021.2021.0325 [doi]
PST - ppublish
SO  - Turk J Haematol. 2022 Jun 1;39(2):109-116. doi: 
      10.4274/tjh.galenos.2021.2021.0325. Epub 2021 Nov 26.